Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The usefulness of the ratio of antigen-autoantibody immune complexes to their free antigen in the diagnosis of non-small cell lung cancer

Version 1 : Received: 17 July 2023 / Approved: 17 July 2023 / Online: 18 July 2023 (09:15:30 CEST)

A peer-reviewed article of this Preprint also exists.

Kim, H.; Lee, J.K.; Oh, A.-C.; Kim, H.-R.; Hong, Y.J. The Usefulness of the Ratio of Antigen–Autoantibody Immune Complexes to Their Free Antigens in the Diagnosis of Non-Small Cell Lung Cancer. Diagnostics 2023, 13, 2999. Kim, H.; Lee, J.K.; Oh, A.-C.; Kim, H.-R.; Hong, Y.J. The Usefulness of the Ratio of Antigen–Autoantibody Immune Complexes to Their Free Antigens in the Diagnosis of Non-Small Cell Lung Cancer. Diagnostics 2023, 13, 2999.

Abstract

Autoantibodies against specific lung cancer-associated antigens have been suggested for lung cancer diagnosis. This study aimed to evaluate the diagnostic performance of anti-gen-autoantibody immune complex (AIC) against its free antigens for CYFRA21-1, ProGRP, NGAL, and NSE in non-small cell lung cancer (NSCLC). In total, 85 patients with NSCLC and 120 healthy controls (HCs) were examined using a 9G DNA chip method. The ratios of AICs to their antigens and combinations of ratios consisting of two to four markers were calculated. The levels of AICs for CYFRA21-1, ProGRP, NGAL, and NSE were higher than their free antigens in all participants. The levels of each free antigen distinguished patients with NSCLC from HCs. The ratios of AIC to its antigen and seven combinations consisting of two to four ratios were significantly higher in patients with NSCLC than those in HCs. Excellent diagnostic performance was observed for all combination ratios (C4-1), with 85.9% sensitivity and 86.7% specificity at cutoff 3.51. Higher sensitivity was observed in the very early stages (0–I) and adenocarcinoma than in stages II–IV and other pathological types. The combination of all ratios of AICs and their antigens for all four markers is useful in the diagnosis of NSCLC.

Keywords

lung cancer; non-small cell lung cancer, autoantibody; biomarker; CYFRA21-1; ProGRP; NGAL; NSE

Subject

Medicine and Pharmacology, Other

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.